Combined Treatment Fkt-Botulinum Toxin Type A (Btx-A) in Patients with Strumpell-Lorrain Disease.

Abstract

The Hereditary Spastic Paraparesis (HSP) or Strumpell-Lorrain disease is a heterogeneous neurodegenerative disease of the spinal cord. It is genetically transmitted and characterized by a progressive muscle weakness, spasticity of the lower limbs and awkward gain. There is no specific pharmacological treatment. The pharmacological therapy decreases the… (More)

Topics

Cite this paper

@article{Riccardo2016CombinedTF, title={Combined Treatment Fkt-Botulinum Toxin Type A (Btx-A) in Patients with Strumpell-Lorrain Disease.}, author={Marvulli Riccardo and Lopopolo Angela and D ’ Alfonso Angela and P. Di Vita and Lancioni Giulio and Fiore Pietroq and Ianieri Giancarlo and Megna Marisa}, journal={Current pharmaceutical design}, year={2016}, volume={22 6}, pages={758-63} }